[1] 中华医学会. 丙型肝炎防治指南.中华肝脏病杂志,2004,12(4):194-198. [2] 张英,朱建英,曾丽娇,等. 聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎. 热带医学杂志,2008,8(8):810-812. [3] Yamada G,Takatani M,Kishi F,et al. Efficacy of interferon alfatherapy in chronic hepatitis C virus RNA level. Hepatology,1995,22:1351. [4] Hayes CN,Kobayashi M,Akuta N. HCV substitutions and IL28B polymorphisms on outcome of peg -interferon plus ribavirin combination therapy. Gut,2011,60(2):261-267. [5] 廖祥伟,凌云,李新华,等. 宿主IL28B 基因型联合病毒基因型对慢性丙型肝炎抗病毒疗效的预测. 中国病毒病杂志,2011,1:35-40. [6] Simmonds P,Holmes EC,Cha TA,et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol,1993,74(11):2391-2399. [7] Moreno C,Deltenre P,Pawlotsky JM,et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta analysis. J Hepatol,2010,52(1):25-31. [8] Mangia A,Santoro R,Andriulli A,et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med,2005,352(25):2609-2617. [9] Davis GL,Wong JB,McHutchison JG,et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology,2003,38(3): 645-652. [10] Wong JB,Davis GL,McHutchinson JG,et al. Clinical implications of testing viral response during ribavirin and peginterferon alfa-2b treatment for chronic hepatitis C. Hepatology,2002,36:281A. [11] Yuen MF,Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatits C virus genotype 6 than genotype 1 in HongKong.Intervirology,2006,49(1-2):96-98. [12] 张永祥,孙南雄,黄祖瑚,等. 江苏地区丙型肝炎病毒基因分型研究. 江苏医药,2004,30(6):463-464. [13] 张大军. 60例丙型肝炎患者血清丙型肝炎病毒RNA的基因分析. 中华流行病学杂志,2002,23(6):469. |